In a recently issued opinion, Federal Judge Rudolph Contreras of the U.S. District Court of Washington D.C. reversed cuts to the 340B program as promulgated under the CY 2018 Hospital Outpatient Prospective Payment System (OPPS) final rule. You may recall U.S. Department of Health and Human Services (HHS) slashed Medicare reimbursement for drugs furnished under […]
After delaying the effective date on five separate occasions, the U.S. Department of Health and Human Services (HHS) has sought to implement a final rule that outlines the parameters for calculating 340B ceiling prices and civil monetary penalties for manufacturers who knowingly over charge covered entities. You may recall that several hospital groups sued the […]
In the recently released CY2019 Medicare Outpatient Prospective Payment System (OPPS) final rule, CMS finalized further cuts to the 340B Drug Pricing Program by slashing payment to nonexcepted off-campus provider-based departments (PBDs) and biosimilar products without pass-through status. For background, PBDs form when hospitals acquire physician offices. A non-excepted PBD is one that does not […]
In the flurry of calls for increased transparency and clarification regarding the 340B Drug Discount Program, the American Hospital Association (AHA) and individual 340B hospitals have issued a set of stewardship principles. In a press release, Rick Pollack, President and CEO of the AHA, said these “340B stewardship principles will help hospitals better tell their […]
Read our latest specialty pharmacy insight report here.